Institutional members access full text with Ovid®

FDA Approves First Drug for Endogenous Cushing's Syndrome

Aschenbrenner, Diane S. MS, RN

AJN, American Journal of Nursing: June 2012 - Volume 112 - Issue 6 - pp 26,27
doi: 10.1097/01.NAJ.0000415123.61735.8e
Drug Watch

* Korlym is the first drug approved to help treat endogenous Cushing's syndrome, a rare condition in which the adrenal glands overproduce cortisol. Korlym is a formulation of mifepristone and works by controlling hyperglycemia or type 2 diabetes associated with the disease.

* Korlym's most common adverse effects are nausea, fatigue, headache, arthralgia, vomiting, peripheral edema, dizziness, decreased appetite, and endometrial hypertrophy. Other potentially serious adverse effects include adrenal insufficiency, low potassium levels, vaginal bleeding, and QT interval prolongation.

Diane S. Aschenbrenner is the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch:

© 2012 Lippincott Williams & Wilkins, Inc.